Payment overview · 2025
General Payments
$762.99
36 reported records · 17 companies
Healthcare provider profile · identity verified
Lance S Patton, M.D.
Allopathic & Osteopathic Physicians|Internal Medicine · JEFFERSON CITY, TN · NPI 1104822816
Verified facts
What the public records show
CMS Open Payments records show Lance S Patton, M.D. received $762.99 in general payments during 2025 across 36 reported records.
Novo Nordisk Inc accounted for 19.9% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 24 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Abrysvo, Eliquis, Ozempic, Shingrix, Trelegy Ellipta.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYMBICORT as an associated drug or biological on 71 records involving 51 distinct recipient NPIs. Public Medicare Part D data also shows 23 claims for Symbicort by this doctor in 2024.
E.R. Squibb & Sons, L.L.C. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 27956 records involving 14870 distinct recipient NPIs. Public Medicare Part D data also shows 126 claims for Eliquis by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SHINGRIX as an associated drug or biological on 43515 records involving 26794 distinct recipient NPIs. Public Medicare Part D data also shows 54 claims for Shingrix by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 43 claims for Trelegy Ellipta by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 32 claims for Ozempic by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ABRYSVO as an associated drug or biological on 55380 records involving 31565 distinct recipient NPIs. Public Medicare Part D data also shows 59 claims for Abrysvo by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 126 claims for Eliquis by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $152.25 | 19.9% | 8 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $133.75 | 17.5% | 7 | 2025 |
| HEARTFLOW, INC. | Unresolved — no canonical attribution shown | $93.39 | 12.2% | 2 | 2025 |
| Gilead Sciences, Inc. | Unresolved — no canonical attribution shown | $54.03 | 7.1% | 2 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $51.59 | 6.8% | 3 | 2025 |
| E.R. Squibb & Sons, L.L.C. | Unresolved — no canonical attribution shown | $51.33 | 6.7% | 3 | 2025 |
| Medtronic, Inc. |
Medtronic, Inc. exact · evidence 2025-07-22 |
$27.34 | 3.6% | 1 | 2025 |
| Axsome Therapeutics, Inc. | Unresolved — no canonical attribution shown | $24.94 | 3.3% | 1 | 2025 |
| Boston Scientific Corporation | Unresolved — no canonical attribution shown | $24.83 | 3.2% | 1 | 2025 |
| JAZZ PHARMACEUTICALS INC. | Unresolved — no canonical attribution shown | $24.38 | 3.2% | 1 | 2025 |
| Dexcom, Inc. | Unresolved — no canonical attribution shown | $20.96 | 2.8% | 1 | 2025 |
| Inspire Medical Systems, Inc. | Unresolved — no canonical attribution shown | $20.23 | 2.6% | 1 | 2025 |
| Phathom Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $18.59 | 2.4% | 1 | 2025 |
| SANOFI-AVENTIS U.S. LLC | Unresolved — no canonical attribution shown | $18.56 | 2.4% | 1 | 2025 |
| Xeris Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $16.35 | 2.1% | 1 | 2025 |
| Itamar Medical Inc | Unresolved — no canonical attribution shown | $16.30 | 2.1% | 1 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $14.17 | 1.9% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $762.99 | 36 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $132.25 | 7 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $112.72 | 6 | 2025 |
Source payment records
|
|||||
| TRELEGY ELLIPTA Normalized: trelegy ellipta |
Drug | GlaxoSmithKline, LLC. | $111.67 | 6 | 2025 |
Source payment records
|
|||||
| FFRct Normalized: ffrct |
Device | HEARTFLOW, INC. | $93.39 | 2 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $31.94 | 2 | 2025 |
Source payment records
|
|||||
| ZAVZPRET Normalized: zavzpret |
Drug | PFIZER INC. | $31.94 | 2 | 2025 |
Source payment records
|
|||||
| ELIQUIS Normalized: eliquis |
Drug | E.R. Squibb & Sons, L.L.C. | $29.49 | 2 | 2025 |
Source payment records
|
|||||
| MINIMED 780G Normalized: minimed 780g |
Device | Medtronic, Inc. | $27.34 | 1 | 2025 |
Source payment records
|
|||||
| Sunosi Normalized: sunosi |
Drug | Axsome Therapeutics, Inc. | $24.94 | 1 | 2025 |
Source payment records
|
|||||
| General - Erectile Dysfunction Normalized: general erectile dysfunction |
Device | Boston Scientific Corporation | $24.83 | 1 | 2025 |
Source payment records
|
|||||
| XYWAV Normalized: xywav |
Drug | JAZZ PHARMACEUTICALS INC. | $24.38 | 1 | 2025 |
Source payment records
|
|||||
| SHINGRIX Normalized: shingrix |
Biological | GlaxoSmithKline, LLC. | $22.08 | 1 | 2025 |
Source payment records
|
|||||
| CAMZYOS Normalized: camzyos |
Drug | E.R. Squibb & Sons, L.L.C. | $21.84 | 1 | 2025 |
Source payment records
|
|||||
| Dexcom G6 Transmitter Normalized: dexcom g6 transmitter |
Medical Supply | Dexcom, Inc. | $20.96 | 1 | 2025 |
Source payment records
|
|||||
| INSPIRE Normalized: inspire |
Device | Inspire Medical Systems, Inc. | $20.23 | 1 | 2025 |
Source payment records
|
|||||
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $20.00 | 1 | 2025 |
Source payment records
|
|||||
| ABRYSVO Normalized: abrysvo |
Biological | PFIZER INC. | $19.65 | 1 | 2025 |
Source payment records
|
|||||
| COMIRNATY Normalized: comirnaty |
Biological | PFIZER INC. | $19.65 | 1 | 2025 |
Source payment records
|
|||||
| VOQUEZNA Normalized: voquezna |
Drug | Phathom Pharmaceuticals, Inc. | $18.59 | 1 | 2025 |
Source payment records
|
|||||
| TZIELD Normalized: tzield |
Biological | SANOFI-AVENTIS U.S. LLC | $18.56 | 1 | 2025 |
Source payment records
|
|||||
| AREXVY Normalized: arexvy |
Biological | GlaxoSmithKline, LLC. | $18.33 | 1 | 2025 |
Source payment records
|
|||||
| GVOKE HYPOPEN Normalized: gvoke hypopen |
Drug | Xeris Pharmaceuticals, Inc. | $16.35 | 1 | 2025 |
Source payment records
|
|||||
| WatchPATONE Normalized: watchpatone |
Device | Itamar Medical Inc | $16.30 | 1 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $14.17 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| ABRYSVO abrysvo |
2025 | Abrysvo | 2024 | 59 | exact normalized | Medicare Part D |
| ELIQUIS eliquis |
2025 | Eliquis | 2024 | 126 | exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 32 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| SHINGRIX shingrix |
2025 | Shingrix | 2024 | 54 | exact normalized | Medicare Part D |
| TRELEGY ELLIPTA trelegy ellipta |
2025 | Trelegy Ellipta | 2024 | 43 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | SYMBICORT open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 51 recipient NPIs · example record 1206132610 |
Symbicort · 2024 Exact normalized brand match · 1 Part D row |
23 | suppressed by CMS |
| E.R. Squibb & Sons, L.L.C. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 27956 supporting records · 14870 recipient NPIs · example record 1184377713 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
126 | 31 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | SHINGRIX open payments reported associated product |
CMS Open Payments — General Payments 43515 supporting records · 26794 recipient NPIs · example record 1190332452 |
Shingrix · 2024 Exact normalized brand match · 1 Part D row |
54 | 39 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
43 | 11 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
32 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ABRYSVO open payments reported associated product |
CMS Open Payments — General Payments 55380 supporting records · 31565 recipient NPIs · example record 1228794147 |
Abrysvo · 2024 Exact normalized brand match · 1 Part D row |
59 | 59 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
126 | 31 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 395 | 100 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 379 | 115 |
| Levothyroxine Sodium | Levothyroxine Sodium | 366 | 83 |
| Amlodipine Besylate | Amlodipine Besylate | 337 | 94 |
| Pantoprazole Sodium | Pantoprazole Sodium | 230 | 55 |
| Lisinopril | Lisinopril | 181 | 46 |
| Tramadol Hcl | Tramadol Hcl | 180 | 33 |
| Omeprazole | Omeprazole | 172 | 43 |
| Gabapentin | Gabapentin | 154 | 38 |
| Metoprolol Succinate | Metoprolol Succinate | 151 | 48 |
| Tamsulosin Hcl | Tamsulosin Hcl | 141 | 30 |
| Montelukast Sodium | Montelukast Sodium | 139 | 35 |
| Metformin Hcl Er | Metformin Hcl | 135 | 45 |
| Metoprolol Tartrate | Metoprolol Tartrate | 132 | 29 |
| Donepezil Hcl | Donepezil Hcl | 129 | suppressed |
| Eliquis | Apixaban | 126 | 31 |
| Hydralazine Hcl | Hydralazine Hcl | 126 | 12 |
| Mirtazapine | Mirtazapine | 121 | 25 |
| Sotalol | Sotalol Hcl | 121 | suppressed |
| Losartan Potassium | Losartan Potassium | 120 | 39 |
| Citalopram Hbr | Citalopram Hydrobromide | 117 | 15 |
| Allopurinol | Allopurinol | 112 | 29 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 109 | 38 |
| Clopidogrel | Clopidogrel Bisulfate | 106 | 18 |
| Spironolactone | Spironolactone | 100 | 19 |
| Carvedilol | Carvedilol | 99 | 14 |
| Metformin Hcl | Metformin Hcl | 90 | 28 |
| Ezetimibe | Ezetimibe | 89 | 29 |
| Hydrochlorothiazide | Hydrochlorothiazide | 87 | 26 |
| Chlorthalidone | Chlorthalidone | 84 | 25 |
| Furosemide | Furosemide | 83 | 31 |
| Sertraline Hcl | Sertraline Hcl | 83 | 26 |
| Tizanidine Hcl | Tizanidine Hcl | 83 | 12 |
| Fluoxetine Hcl | Fluoxetine Hcl | 81 | 11 |
| Fluticasone Propionate | Fluticasone Propionate | 80 | 29 |
| Jardiance | Empagliflozin | 79 | 16 |
| Valsartan | Valsartan | 73 | 22 |
| Duloxetine Hcl | Duloxetine Hcl | 71 | 25 |
| Escitalopram Oxalate | Escitalopram Oxalate | 71 | 19 |
| Trazodone Hcl | Trazodone Hcl | 65 | 14 |
| Potassium Chloride | Potassium Chloride | 60 | 20 |
| Abrysvo | Rsv Vacc, Pref A And Pref B/Pf | 59 | 59 |
| Lovastatin | Lovastatin | 59 | suppressed |
| Shingrix | Varicella-Zoster Ge/As01b/Pf | 54 | 39 |
| Diltiazem Hcl | Diltiazem Hcl | 53 | suppressed |
| Bumetanide | Bumetanide | 51 | suppressed |
| Glimepiride | Glimepiride | 50 | 15 |
| Potassium Citrate Er | Potassium Citrate | 49 | suppressed |
| Famotidine | Famotidine | 47 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 46 | suppressed |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 45 | 11 |
| Simvastatin | Simvastatin | 44 | 12 |
| Warfarin Sodium | Warfarin Sodium | 44 | 11 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 43 | 11 |
| Pravastatin Sodium | Pravastatin Sodium | 42 | 14 |
| Azithromycin | Azithromycin | 40 | 31 |
| Buspirone Hcl | Buspirone Hcl | 40 | 11 |
| Varenicline Tartrate | Varenicline Tartrate | 40 | 22 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 39 | 13 |
| Nebivolol Hcl | Nebivolol Hcl | 37 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 36 | suppressed |
| Atenolol | Atenolol | 35 | 11 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 35 | 12 |
| Alendronate Sodium | Alendronate Sodium | 33 | 16 |
| Nystatin | Nystatin | 33 | 18 |
| Xarelto | Rivaroxaban | 33 | suppressed |
| Divalproex Sodium | Divalproex Sodium | 32 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 32 | suppressed |
| Novolog Flexpen | Insulin Aspart | 32 | suppressed |
| Ozempic | Semaglutide | 32 | suppressed |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 32 | 13 |
| Irbesartan | Irbesartan | 31 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 30 | 24 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 30 | suppressed |
| Mupirocin | Mupirocin | 30 | 22 |
| Finasteride | Finasteride | 28 | suppressed |
| Boostrix Tdap | Diphth,pertuss(Acell),tet Vac | 27 | 27 |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 27 | suppressed |
| Pregabalin | Pregabalin | 27 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 26 | suppressed |
| Clonazepam | Clonazepam | 25 | suppressed |
| Prednisone | Prednisone | 25 | 15 |
| Fluconazole | Fluconazole | 23 | 14 |
| Symbicort | Budesonide/Formoterol Fumarate | 23 | suppressed |
| Colchicine | Colchicine | 21 | 11 |
| Zolpidem Tartrate | Zolpidem Tartrate | 21 | 14 |
| Dropsafe Prep Pads | Alcohol Antiseptic Pads | 20 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 20 | suppressed |
| Fenofibrate | Fenofibrate | 19 | suppressed |
| Synthroid | Levothyroxine Sodium | 18 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 18 | suppressed |
| Cephalexin | Cephalexin | 17 | 16 |
| Enalapril Maleate | Enalapril Maleate | 17 | suppressed |
| Levofloxacin | Levofloxacin | 17 | 12 |
| Nitroglycerin | Nitroglycerin | 17 | suppressed |
| Prolia | Denosumab | 17 | 11 |
| Januvia | Sitagliptin Phosphate | 16 | suppressed |
| Meloxicam | Meloxicam | 16 | suppressed |
| Ondansetron Odt | Ondansetron | 16 | 14 |
| Amoxicillin | Amoxicillin | 15 | 15 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 15 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 15 | suppressed |
| Spiriva Respimat | Tiotropium Bromide | 15 | suppressed |
| Amiodarone Hcl | Amiodarone Hcl | 14 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 14 | suppressed |
| Bisoprolol Fumarate | Bisoprolol Fumarate | 14 | suppressed |
| Epinephrine | Epinephrine | 14 | suppressed |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 14 | suppressed |
| Irbesartan-Hydrochlorothiazide | Irbesartan/Hydrochlorothiazide | 14 | suppressed |
| Memantine Hcl | Memantine Hcl | 14 | suppressed |
| Aripiprazole | Aripiprazole | 13 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 13 | suppressed |
| Mounjaro | Tirzepatide | 13 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 13 | 12 |
| Repatha Sureclick | Evolocumab | 13 | suppressed |
| Sucralfate | Sucralfate | 13 | suppressed |
| Calcitriol | Calcitriol | 12 | suppressed |
| Toujeo Max Solostar | Insulin Glargine,hum.Rec.Anlog | 12 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 11 | suppressed |
| Celecoxib | Celecoxib | 11 | suppressed |
| Latanoprost | Latanoprost | 11 | suppressed |
| Myrbetriq | Mirabegron | 11 | suppressed |
| Topiramate | Topiramate | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $762.99 · 36 records | Novo Nordisk Inc | ABRYSVO, AIRSUPRA, AREXVY, CAMZYOS, COMIRNATY, Dexcom G6 Transmitter, ELIQUIS, FFRct, GVOKE HYPOPEN, General - Erectile Dysfunction, INSPIRE, MINIMED 780G, NURTEC ODT, Ozempic, Rybelsus, SHINGRIX, Sunosi, TRELEGY ELLIPTA, TZIELD, VOQUEZNA, WatchPATONE, Wegovy, XYWAV, ZAVZPRET | 7 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Abrysvo play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with AstraZeneca Pharmaceuticals LP?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error